WEKO3
アイテム
頭頸部領域腺癌系腫瘍のメチオニンPETによる重粒子線治療予後評価の研究
https://repo.qst.go.jp/records/62696
https://repo.qst.go.jp/records/6269697a6f640-fc2a-41e6-b040-ed671c820bc1
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2008-09-03 | |||||
| タイトル | ||||||
| タイトル | 頭頸部領域腺癌系腫瘍のメチオニンPETによる重粒子線治療予後評価の研究 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
長谷部, 充彦
× 長谷部, 充彦× 吉川, 京燦× Ｓｈｅｒｉｆ, Ｍａｈｍｏｕｄ Ａｂｄ−Ｅｌｒａｚｅｋ Ｈｅｌｍｙ× 石川, 博之× 佐合, 賢治× 田村, 克巳× 神立, 進× 溝江, 純悦× 佐賀, 恒夫× 鈴木, 和年× 辻井, 博彦× 長谷部 充彦× 吉川 京燦× Ｓｈｅｒｉｆ Ｍａｈｍｏｕｄ Ａｂｄ−Ｅｌｒａｚｅｋ Ｈｅｌｍｙ× 石川 博之× 佐合 賢治× 田村 克巳× 神立 進× 溝江 純悦× 佐賀 恒夫× 鈴木 和年× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | PURPOSE: The purpose of this study is to assess the ability of C-11 methionine PET (MET-PET) to predict prognosis of patient with adenocarcinoma in head and neck treated by carbon ion radiotherapy (CIRT). METHOD AND MATERIALS: We studied consecutive 23(male: 15, female: 8) patients with proven adenocarcinoma in head and neck who had been referred to our hospital for CIRT. The average patient age was 61.9 years (range 40 to 82). Patients were followed for 5.1 to 89.8 months (mean: 31.9 months) after CIRT. We evaluated the lesion semi-quantitatively on the basis of the Tumor-to-Normal-tissue Ratio (TNR). We statistically analyzed the relationship between tumor MET uptake level at pre and post CIRT. RESULTS: There were significant relationships between the level of tumor activity before CIRT and patients prognosis, recurrence and metastasis rate (p=0.029, 0.043, and 0.014) from Kaplan-Meier analysis. The level of tumor activity after CIRT also significantly related to patients prognosis, recurrence and metastasis rate (p=0.049, 0.043, and 0.014). No statistically significant relationship was observed between tumor uptake change after CIRT and survival rate. CONCLUSIONS:MET-PET is useful to predict patients survival rate, recurrence and metastasis rate in patients with head and neck adenocarcinoma treated by CIRT. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | H19年度HIMAC共同利用研究成果発表会 | |||||
| 発表年月日 | ||||||
| 日付 | 2008-04-15 | |||||
| 日付タイプ | Issued | |||||
